Journal of Immunology Research

Novel Cancer Immunotherapies and Antitumor Immunity


Publishing date
01 Dec 2018
Status
Published
Submission deadline
03 Aug 2018

Lead Editor
Guest Editors

1PLA General Hospital, Beijing, China

2University of Texas MD Anderson Cancer Center, Houston, USA

3Beijing Institute of Pharmacology and Toxicology, Beijing, China


Novel Cancer Immunotherapies and Antitumor Immunity

Description

Nowadays, antibody has been widely used in cancer treatment. However, due to the complexity and heterogeneity of cancer, the acquired resistance is one of the prime obstacles in the way of cancer treatment and development of novel cancer immunotherapies with potent antitumor activities and specificities are urgently needed. Recently, the success of PD-1/PD-L1 therapeutic antibodies in clinic has revealed that blockade of tumor-associated immunosuppression and initiation of tumor-specific immunity could be critical for the development of novel immunotherapies against cancer. How to efficiently induce tumor-specific immunity would be important for the development of novel cancer immunotherapies in the future.

The high-quality original research articles as well as review articles are invited to understand and clarify the related knowledge and mechanism of antitumor immune response and contribute to the development of novel cancer immunotherapies with high efficacy to induce antitumor immunity.

Potential topics include but are not limited to the following:

  • Tumor microenvironment and antitumor immunity
  • Restoration of immunoactive microenvironment for antitumor immunity
  • Alleviation of immunosuppressive microenvironment for antitumor immunity
  • Design of novel cancer immunotherapies, including strategies or agents to modulate antitumor immunity
  • Biomarkers for personalizing cancer immunotherapy, including immune-checkpoint blockade or immune cell therapy
  • New drug carriers, especially nanoparticles, for cancer target drug delivery

Articles

  • Special Issue
  • - Volume 2019
  • - Article ID 3742061
  • - Editorial

Novel Cancer Immunotherapies and Antitumor Immunity

Lei Zhao | Jianjun Zhang | ... | Hussein A. Abbas
  • Special Issue
  • - Volume 2019
  • - Article ID 1242979
  • - Research Article

Cervical Cancer Cells Express Markers Associated with Immunosurveillance

Adriana Gutiérrez-Hoya | Octavio Zerecero-Carreón | ... | Isabel Soto-Cruz
  • Special Issue
  • - Volume 2019
  • - Article ID 1749803
  • - Research Article

pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG

Jing Wu | Shuang Li | ... | Jingtao Chen
  • Special Issue
  • - Volume 2019
  • - Article ID 4516041
  • - Review Article

Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy

Shixue Chen | Lingling Li | ... | Lei Zhao
  • Special Issue
  • - Volume 2019
  • - Article ID 6705949
  • - Research Article

Implementation of Mass Cytometry for Immunoprofiling of Patients with Solid Tumors

Ingrid Poláková | Ondřej Pelák | ... | Michal Šmahel
  • Special Issue
  • - Volume 2019
  • - Article ID 3017360
  • - Research Article

A Novel Anti-EGFR mAb Ame55 with Lower Toxicity and Better Efficacy than Cetuximab When Combined with Irinotecan

Weiyi Qiu | Chang Zhang | ... | Zhiwei Sun
  • Special Issue
  • - Volume 2018
  • - Article ID 4325874
  • - Review Article

Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens

Ren-You Pan | Wen-Hung Chung | ... | Shuen-Iu Hung
  • Special Issue
  • - Volume 2018
  • - Article ID 9081938
  • - Research Article

The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials

Zheng Xiao | Cheng-qiong Wang | ... | Ji-hong Feng
  • Special Issue
  • - Volume 2018
  • - Article ID 2942679
  • - Research Article

HLA-A2-Restricted Epitopes Identified from MTA1 Could Elicit Antigen-Specific Cytotoxic T Lymphocyte Response

Yahong Wu | Wenjie Zhai | ... | Yanfeng Gao
  • Special Issue
  • - Volume 2018
  • - Article ID 1090287
  • - Research Article

EGFR-Targeted Immunotoxin Exerts Antitumor Effects on Esophageal Cancers by Increasing ROS Accumulation and Inducing Apoptosis via Inhibition of the Nrf2-Keap1 Pathway

Yun Yang | Ziyin Tian | ... | Rui Guo
Journal of Immunology Research
 Journal metrics
Acceptance rate45%
Submission to final decision61 days
Acceptance to publication37 days
CiteScore5.100
Impact Factor3.327
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.